Surviving Pneumonia
ConditionCommunity-acquired Pneumonia
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorNordsjaellands Hospital
About this trial
The study aims to explore risk factors for poor prognosis among patients admitted with community-acquired pneumonia (CAP). During a 5-year study period, all patients (aged ≥ 18 years) admitted with CAP at North Zealand Hospital will be invited for inclusion. Questionnaires, anthropometric measures, laboratory tests, and biomaterials will be collected at admission, daily during admission, at discharge and at follow-up. The main clinical outcomes of the study consist of deaths and development of diabetes.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Fever (temperature, ≥38.0°C)
Hypothermia (<35.0°C),
New cough with or without sputum production
Pleuritic chest pain
Disqualifiers
Patients unable to give informed consent
Patients unwilling to give informed consent
Trial population
Adults (≥18 years) admitted with community-acquired pneumonia
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
No intervention
Other interventionObervational
Treatment groups
2,500 Participants
are divided into 1 treatment groupGroup A: Community-acquired pneumonia1 intervention
Trial outcomes
Primary outcomes
1
Number of death from any causes
Assessed through patient files
Time frame
From date of admission until the day of death from any causes, up to 24 months2
Number of participants who develop diabetes
Assessed through patient files and the national registers
Time frame
Up to 24 monthsSecondary outcomes
1
Length of hospital stay
Through patient files
Time frame
Participants will be followed for the duration of hospital stay, an expected average of 5 days2
Oral glucose tolerance test
Time frame
Day 1, discharge (an average of 5 days), 1 month and 6-month3
Number of participants who are readmitted
Through patient files
Time frame
Up to 6 monthsOther outcomes
1
Facal sample to assess changes in microbiome
Time frame
Day 1, 1 month and 6 months2
Urine samples to assess metabolomics
Time frame
Day 1, 1 month and 6 months3
Physical activity monitoring (measured by the AX3 accelerometers)
Time frame
During admission (up to 7 days), 14 days from discharge (an average of 5 days)4
Self-reported physical activity by scoring of the international physical activity questionnaire (IPAQ)
Time frame
Day 1Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov